Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 14, 2017
President of Lexaria Bioscience Corp., John Docherty, speaks on the company's technology that allows for the enhanced flavor and faster absorption of edible products.
What's unique about the company is its patented drug delivery technology. Our DehydraTECH technology is a method by which we can combine bioactive molecules like THC or CBD or other molecules like non-steroidal anti-inflammatories at a molecular level with certain types of fatty acids such as oleic acid found in sunflower oil. We call it DehydraTECH because we use a dehydration synthesis methodology and by doing that, it allows the molecules to elude flavor receptors in the mouth, it allows those molecules to be faster acting and better absorbed by the human gastrointestinal tract. The commercial applications of our company and of our technology are principally, by way of out licensing our tech to third party strategic partners who can then use our technology to improve the delivery and flavor performance of their products. And doing all of this in a cost-effective manner. Technology is really the heart of the company and it allows us to be active on a global scale. It allows us to apply this technology to companies in the United States, Canada we've even recently received patent protection in Australia so we offer our stakeholders a means to be participating in the functional food market place for cannabinoids or other bio actives, not only domestically but also on a global scale.
Lexaria Bioscience Corp. evolved into its current form in 2014 upon controlling acquisition of the former company where Lexaria’s DehydraTECH™ technology originated. Since then, Lexaria has quickly emerged as a global leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products while also working to expand the applicability of its technology, within and beyond the cannabinoid sector, through its out-licensing business model for cannabinoids and other bioactive molecules named in its patent portfolio (NSAIDs, nicotine, vitamins and more). Lexaria produces industry-leading research to support its novel delivery method. None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth.
Lexaria has always maximized its resources by attracting top management and advisors and also leveraging the strongest expert consultant relationships. Supporters have included industry leaders, research scientists, clinicians, analytical chemists, intellectual property experts, study volunteers, partnering company collaborators and, of course, the original inventors of the earliest iterations of Lexaria’s DehydraTECH™ technology.